演題詳細

ポスター / Poster

【E】ポスター 43 (Poster 43) :GVHD/Chimerism

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F エメラルドABCD)
座長・司会
岡本 康裕 (Yasuhiro Okamoto):1
1:Department of Pediatrics, Kagoshima University Hospital, Japan
 
前へ戻る

Intentional induction of mixed chimerism using combination cell therapy with human adipose tissue-derived MSC and murine ex vivo-expanded Treg

演題番号 : PS-1-328

Keon-IL Im:1、Jung-Yeon Lim:1、Nayoun Kim:1、Eun-Sol Lee:1、Sang-Min Kim:1、Eun-Jung Kim:1、Seok-Goo Cho:1,2

1:Laboratory of Immune Regulation, Seoul St. Mary’s Hospital, Korea、2:Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, Korea

 

Establishment of mixed chimerism through allogeneic bone marrow transplantation (BMT) has been considered an ideal approach to induce donor-specific tolerance, but BMT-related complications such as regimen-related toxicity, graft rejection and graft-versus-host disease (GVHD) remain a risk. The immunomodulatory functions of mesenchymal stem cells (MSCs) and their potential to enhance graft engraftment have led to their increasing use in transplantation protocols. The induction of regulatory T cells (Tregs) by MSCs has been well characterized in many studies; the interaction between these cells is hypothesized to lead to greater inhibition of host immune responses. We thus investigated whether combination cell therapy with MSCs and Tregs could achieve stable mixed chimerism in an MHCincompatible transplantation setting. Recipients were pre-conditioned with low-dose total body irradiation (150 cGy) and short-course cyclophosphamide (100 mg/kg) and were then treated with human adipose tissue-derived MSCs and ex vivo-expanded Tregs posttransplantation. The combination cell therapy induced a higher rate of graft engraftment and long-term multi-lineage chimerism than therapy with either MSCs or Tregs alone. The chimeras exhibited donor-specific tolerance to skin allografts without the occurrence of GVHD. These results suggest a novel approach to induce stable mixed chimerism and donorspecific tolerance using combination cell therapy.

前へ戻る